Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial

Prophylactic human papillomavirus vaccines such as Cervarix® and Gardasil®9 induce robust and sustained antibody responses over time. One driver of such responses is memory B-cells (MBCs), primed during initial HPV-vaccine exposure. As part of the Dose Reduction Immunobridging and Safety Study (DoRIS), MBCs were evaluated in peripheral blood mononuclear cells by enzyme-linked immunosorbent spot assay at baseline and at 5 visits post-first vaccine dose to Month 36 in 930 Tanzanian girls randomly allocated to 3, 2, or 1 doses of either vaccine. Most ( > 90%) participants had detectable MBCs at all time points, with maximum responses by Month 7. Geometric mean frequency HPV-specific MBCs and the proportion responding declined thereafter for both vaccines in the 2 and 3-dose arms. MBC frequencies were lower in single-dose than in 2- and 3-doses recipients at all time points subsequent to Month 1. By Month 36, MBC responses to both vaccines for both HPV16 and 18 were similar across all dosing arms. The clinical significance of the dose response remains to be evaluated; however, the presence of MBCs in the circulation after 3 years with a single vaccine dose is encouraging in terms of generating long-lasting protection with a one-dose vaccination strategy.

Authors

Institutions

Publication Details

Journal
npj Vaccines
Published
2025-11-28
DOI
https://doi.org/10.1038/s41541-025-01313-8
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial

Philippe Mayaud, Hilary Whitworth, Paul Mutani, Helen Ashwin et al.
npj Vaccines
Cervical Cancer and HPV Research
article

Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial

Philippe Mayaud, Hilary Whitworth, Paul Mutani, Helen Ashwin, Silvia DeSanjose, Kathy J. Baisley, Saidi Kapiga, Rebecca Wiggins, Jackton Indangasi, Lígia A. Pinto, John Changalucha, Ramadhan Hashim, Troy J. Kemp, Brett Lowe, Beatrice Kamala, Charles Lacey, Richard Hayes, Caroline Maxwell, Najmeeyah Brown, Deborah Watson-Jones, David Joakim
article en

Abstract

Prophylactic human papillomavirus vaccines such as Cervarix® and Gardasil®9 induce robust and sustained antibody responses over time. One driver of such responses is memory B-cells (MBCs), primed during initial HPV-vaccine exposure. As part of the Dose Reduction Immunobridging and Safety Study (DoRIS), MBCs were evaluated in peripheral blood mononuclear cells by enzyme-linked immunosorbent spot assay at baseline and at 5 visits post-first vaccine dose to Month 36 in 930 Tanzanian girls randomly allocated to 3, 2, or 1 doses of either vaccine. Most ( > 90%) participants had detectable MBCs at all time points, with maximum responses by Month 7. Geometric mean frequency HPV-specific MBCs and the proportion responding declined thereafter for both vaccines in the 2 and 3-dose arms. MBC frequencies were lower in single-dose than in 2- and 3-doses recipients at all time points subsequent to Month 1. By Month 36, MBC responses to both vaccines for both HPV16 and 18 were similar across all dosing arms. The clinical significance of the dose response remains to be evaluated; however, the presence of MBCs in the circulation after 3 years with a single vaccine dose is encouraging in terms of generating long-lasting protection with a one-dose vaccination strategy.

npj VaccinesVol. 10(1)
University of London (GB), London School of Hygiene & Tropical Medicine (GB), Frederick National Laboratory for Cancer Research (US), Mwanza Intervention Trials Unit (TZ), Barcelona Institute for Global Health (ES), National Institute for Medical Research (TZ), University of York (GB), Hull York Medical School (GB)
Bill and Melinda Gates Foundation, London School of Hygiene and Tropical Medicine, Wellcome Trust, Department for International Development, National Institutes of Health, Medical Research Council, National Cancer Institute
Openalex Percentile: Top 51%
Cervical Cancer and HPV Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.